Jim Palma is Chief Executive Officer of TargetCancer Foundation. Since joining TargetCancer Foundation (TCF) in 2010, Jim has overseen its growth from a small, Boston-based start-up to a nationally recognized foundation driving comprehensive rare cancer research programs and patient support services. Jim is a member of the Board of Directors of the National Organization for Rare Disorders (NORD) and is a founding Co-Chair of the NORD Rare Cancers Coalition. In addition, Jim serves on the Advisory Board of the Transformative Rare Cancer Initiative (TRACER) at the Fred Hutchinson Cancer Center, and is a Steering Committee member at the Global Cholangiocarcinoma Alliance. Jim also serves as a member of the Programmatic Panel of the US Army Medical Research and Development Command Rare Cancers Research Program. Prior to joining TargetCancer Foundation, Jim spent eleven years at Fidelity Investments in Boston, MA. Jim completed studies at the Institute for Nonprofit Management and Leadership at the Questrom School of Business at Boston University, and received his B.A. from Loyola University Maryland.
Alliance for Rare Cancers I Jedi Rare Cancer Foundation
P.O. Box 683501, Park City, Utah 84068
The Alliance for Rare Cancers is a fiscally sponsored program of the Jedi Rare Cancer Foundation, a 501(c)(3) nonprofit organization, accepting tax-deductible donations from individuals, corporations, family-advised funds, and foundations. Federal Tax ID 86-2610819. All donations are tax deductible as allowed by law.
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.